Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Studies Show Diabetes Medicine Can Cause Urologic Complications
SAN ANTONIO, May 5, 2024 (GLOBAL NEWSWIRE)—Abstracts being presented at the American Urological Association's Annual Meeting discuss how certain diabetes medicine can cause an elevated risk for UTIs in men and how healthcare professionals should work collaboratively to monitor patients on SGLT-2 inhibitors, with attention tailored to patient risk factors including sex.
Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6. Brian Inouye, MD, assistant professor of surgery/urology at Albany Medical Center, moderated a virtual press session with the abstract authors, providing key insights into their research.
“These meds are increasingly popular due to their ability to lower cardiovascular events and the risk of end-stage renal disease. They are now first-line therapies for diabetes management in patients with cardiovascular disease, chronic kidney disease, and heart failure,” said Dr. Inouye. “The ways these meds work is by decreasing the reabsorption of glucose from the urine back into the kidneys and bloodstream. The unintended consequence of this is a higher glucose load in the urine. All three of these talks discuss the urologic sequelae we see in our clinics.”
The following abstracts are covered in the moderated panel:
- SGLT2 Inhibitors Associate with Overactive Bladder Symptoms
- Assessing the Risk of Urinary Tract Infections Associated with SGLT2 Inhibitors in Men: A VigiBase Analysis
- Urologic Complications Of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors Differ Between Diabetic Men And Women
A recording of the panel discussion is available to all press registrants. Fill out the registration form on the website to be added to the virtual programming: https://www.auanet.org/AUA2024/register/press-registration
NOTE TO REPORTERS: Presenting authors and moderators are available to discuss their findings. To arrange an interview with an expert, please contact the AUA Communications Team at Communications@AUAnet.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 25,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Media Contact:
Corey Del Bianco, Corporate Communications and Media Relations Manager
410-689-4033, cdelbianco@auanet.org